肝脂肪变性对核（t）ide类似物治疗的HBeAg阳性慢性乙型肝炎

StephenW

BMC Gastroenterol. 2020 May 12;20(1):146. doi: 10.1186/s12876-020-01289-w.
Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study.
Chen YC1,2, Jeng WJ3,4, Hsu CW3,4, Lin CY3,4.
Author information

1
    Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, and University, Linkou, No 5, Fu Hsing Street, Guishan Dist, Taoyuan City, 33302, Taiwan, Republic of China. [email protected].
2
    College of Medicine, Chang Gung University, No.259, Wen Hua 1st Rd., Guishan Dist, Taoyuan City, 33302, Taiwan, Republic of China. [email protected].
3
    Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, and University, Linkou, No 5, Fu Hsing Street, Guishan Dist, Taoyuan City, 33302, Taiwan, Republic of China.
4
    College of Medicine, Chang Gung University, No.259, Wen Hua 1st Rd., Guishan Dist, Taoyuan City, 33302, Taiwan, Republic of China.

Abstract
BACKGROUND:

The impact of hepatic steatosis (HS) on treatment response following nucleos(t)ide analogue (NA) treatment for chronic hepatitis B (CHB) patients has not been clearly elucidated. We aimed to investigate the difference in HBeAg seroclearance between NA-treated HBeAg-positive CHB patients with and without HS.
METHODS:

We retrospectively recruited HBeAg-positive CHB patients receiving liver biopsy and NA monotherapy. The baseline clinical characteristics and cumulative incidence of HBeAg seroclearance were compared between patients with and without HS and age/gender-matched subgroup analysis was performed.
RESULTS:

A total of 196 patients were enrolled from 2003 April to 2016 October. The mean age was 39.6 ± 11.2 years, 142 (72.4%) were males and 94 (48%) had histological evidence of HS. Median treatment duration and follow-up period were 24.3 months and 54.9 months, respectively. HBeAg seroclearance was achieved in 56/102 (54.9%) and 54/94 (57.4%) patients with and without HS, respectively (p = 0.830). The 5-year cumulative incidence of HBeAg seroclearance in patients with and without HS was 62.8 and 67.7% in overall population (p = 0.398) and 62.4 and 66.9% in age/gender-matched subgroups (p = 0.395), respectively. The rate of HBeAg seroclearance was comparable between patients with or without HS in different NA monotherapy (all p > 0.05).
CONCLUSIONS:

HS had no significant impact on HBeAg seroclearance in HBeAg-positive CHB patients with NA monotherapy during long-term follow-up.
KEYWORDS:

Chronic hepatitis B; HBeAg seroclearance; Hepatic steatosis; Nucleos(t)ide analogue treatment

PMID:
    32397963
DOI:
    10.1186/s12876-020-01289-w

StephenW

BMC胃肠。 2020年5月12日; 20（1）：146。 doi：10.1186 / s12876-020-01289-w。
肝脂肪变性对核（t）ide类似物治疗的HBeAg阳性慢性乙型肝炎的治疗反应的影响：一项回顾性研究。
Chen YC1,2，Jeng WJ3,4，Hsu CW3,4，Lin CY3,4。
作者信息

1个
    中国台湾桃园市桂山区扶兴街5号林口林口长庚纪念医院暨大学消化内科。 [email protected]。
2
    中国台湾省桃园市龟山区文化第一路259号长庚大学医学院[email protected]。
3
    中国台湾桃园市桂山区扶兴街5号林口林口长庚纪念医院暨大学消化内科。
4
    中国台湾省桃园市龟山区文化第一路259号长庚大学医学院

抽象
背景：

尚没有明确阐明对慢性乙型肝炎（CHB）患者进行核苷类似物（NA）治疗后肝脂肪变性（HS）对治疗反应的影响。我们的目的是调查NA治疗的HBeAg阳性CHB患者（有或没有HS）之间HBeAg血清清除率的差异。
方法：

我们回顾性招募了接受肝活检和NA单一疗法的HBeAg阳性CHB患者。比较有无HS患者的基线临床特征和HBeAg血清清除率的累积发生率，并进行年龄/性别匹配的亚组分析。
结果：

从2003年4月到2016年10月，总共196例患者入组。平均年龄为39.6±11.2岁，男性为142例（占72.4％），有94例（占48％）有HS的组织学证据。中位治疗时间和随访时间分别为24.3个月和54.9个月。在有和没有HS的患者中，分别有56/102（54.9％）和54/94（57.4％）的患者实现了HBeAg血清清除（p = 0.830）。有和没有HS的患者5年累计HBeAg血清清除率在总人群中分别为62.8和67.7％（p = 0.398），在年龄/性别匹配的亚组中分别为62.4和66.9％（p = 0.395）。在不同的NA单一疗法中，有或没有HS的患者之间的HBeAg血清清除率是可比的（所有p> 0.05）。
结论：

在长期随访期间，HS对NA单一疗法的HBeAg阳性CHB患者的HBeAg血清清除没有明显影响。
关键字：

慢性乙型肝炎； HBeAg血清清除；肝脂肪变性；核苷类似物治疗

PMID：
    32397963
DOI：
    10.1186 / s12876-020-01289-w

StephenW

https://bmcgastroenterol.biomedc ... /s12876-020-01289-w